Skip to content

Study · Animal study (in vivo) · mouse · 2015

5 results

Intraperitoneal injection of the pancreatic peptide amylin potently reduces behavioral impairment and brain amyloid pathology in murine models of Alzheimer's disease.

Zhu H, Wang X, Wallack M, Li H, Carreras I, Dedeoglu A, Hur JY, Zheng H, Li H, Fine R, Mwamburi M, Sun X, Kowall N, Stern RA, Qiu WQ

Molecular psychiatry11 Mar 2014Cited by 88 (Europe PMC)

PMID24614496 (opens in a new tab)PMCIDPMC4161670 (opens in a new tab)DOI10.1038/mp.2014.17 (opens in a new tab)PepBankPUB-24614496
Read at sourcePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In Alzheimer's disease mouse models, chronic pramlintide injections reduced brain amyloid burden.

    In plain wordsIn mice with Alzheimer's disease models, chronic pramlintide injections reduced brain amyloid burden.

    Peptide
    Pramlintide (Symlin)
    Outcome
    DecreaseBrain amyloid burden
    Study

    mousen: not reported in source

    Alzheimer's disease mouse models
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated · intraperitoneal · chronicAs given in this study (mouse).

    Source sentences

    Summary
    Surprisingly, chronic intraperitoneal (i.p.) injection of AD animals with either amylin or pramlintide reduces the amyloid burden as well as lowers the concentrations of Aβ in the brain.
    1 context sentence
    Summary · context
    Using AD mouse models, we investigated the effects of amylin and its clinical analog, pramlintide, on AD pathogenesis.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In Alzheimer's disease mouse models, chronic pramlintide injections lowered brain Aβ concentrations.

    In plain wordsIn mice with Alzheimer's disease models, chronic pramlintide injections lowered brain Aβ levels.

    Peptide
    Pramlintide (Symlin)
    Outcome
    DecreaseBrain Aβ concentrations
    Study

    mousen: not reported in source

    Alzheimer's disease mouse models
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated · intraperitoneal · chronicAs given in this study (mouse).

    Source sentences

    Summary
    Surprisingly, chronic intraperitoneal (i.p.) injection of AD animals with either amylin or pramlintide reduces the amyloid burden as well as lowers the concentrations of Aβ in the brain.
    1 context sentence
    Summary · context
    Using AD mouse models, we investigated the effects of amylin and its clinical analog, pramlintide, on AD pathogenesis.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In Alzheimer's disease mouse models, pramlintide significantly improved learning and memory assessed with Y maze and Morris water maze tests.

    In plain wordsIn mice with Alzheimer's disease models, pramlintide improved learning and memory on behavioral tests.

    Peptide
    Pramlintide (Symlin)
    Outcome
    IncreaseLearning and memory
    Study

    mousen: not reported in source

    Alzheimer's disease mouse models
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    Dose not stated · intraperitoneal · chronicAs given in this study (mouse).

    Source sentences

    Summary
    These treatments significantly improve their learning and memory assessed by two behavioral tests, Y maze and Morris water maze.
    2 context sentences
    Summary · context
    Surprisingly, chronic intraperitoneal (i.p.) injection of AD animals with either amylin or pramlintide reduces the amyloid burden as well as lowers the concentrations of Aβ in the brain.
    Summary · context
    Using AD mouse models, we investigated the effects of amylin and its clinical analog, pramlintide, on AD pathogenesis.
  4. 04AnimalAnimal study (in vivo)Activity measurement

    In Alzheimer's disease mouse models, pramlintide increased cerebrospinal fluid Aβ1-42 concentrations.

    In plain wordsIn mice with Alzheimer's disease models, pramlintide increased Aβ1-42 levels in fluid around the brain.

    Peptide
    Pramlintide (Symlin)
    Outcome
    IncreaseCSF Aβ1-42 concentrations
    Study

    mousen: not reported in source

    Alzheimer's disease mouse models
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated · intraperitonealAs given in this study (mouse).

    Source sentences

    Summary
    Both amylin and pramlintide treatments increase the concentrations of Aβ1-42 in cerebral spinal fluid (CSF).
    1 context sentence
    Summary · context
    Using AD mouse models, we investigated the effects of amylin and its clinical analog, pramlintide, on AD pathogenesis.
  5. 05AnimalAnimal study (in vivo)Activity measurement

    In Alzheimer's disease mouse models, a single pramlintide injection induced a serum Aβ surge proportional to brain Aβ content.

    In plain wordsIn mice with Alzheimer's disease models, one pramlintide injection raised blood Aβ in proportion to brain Aβ levels.

    Peptide
    Pramlintide (Symlin)
    Outcome
    IncreaseSerum Aβ surge
    Study

    mousen: not reported in source

    Alzheimer's disease mouse models
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated · intraperitoneal · single injectionAs given in this study (mouse).

    Source sentences

    Summary
    A single i.p. injection of either peptide also induces a surge of Aβ in the serum, the magnitude of which is proportionate to the amount of Aβ in brain tissue.
    1 context sentence
    Summary · context
    Using AD mouse models, we investigated the effects of amylin and its clinical analog, pramlintide, on AD pathogenesis.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.